Apidra, an insulin glulisine injection, received FDA approval in 2004. The drug is a rapid-acting mealtime insulin used to improve glycemic control in adults and children with diabetes mellitus [1].
What is insulin glulisine and how does Apidra work?
Insulin glulisine is a rapid-acting analog of human insulin. It works by lowering blood glucose levels after meals. It is absorbed more quickly and begins to work sooner than regular human insulin [1].
What is the Apidra prescribing information and label?
The Apidra label includes information on indications, dosage, administration, contraindications, warnings and precautions, adverse reactions, and drug interactions. It is indicated for subcutaneous injection in the abdomen, thigh, or upper arm, or for intravenous infusion by a healthcare professional [1].
When does Apidra's patent expire?
The primary patent for Apidra, U.S. Patent No. 5,750,587, expired in September 2018. Other related patents may have different expiry dates [2]. Information on patent expiry for Apidra and other drugs is available through DrugPatentWatch.com [2].
Are there generic versions of Apidra available?
Following patent expiry, generic versions of Apidra can be developed and potentially approved by the FDA. The availability of generics depends on factors such as the existence of other market exclusivities and the successful development and approval of biosimilar or generic products [2].
What are the potential risks and side effects of Apidra?
Common side effects associated with Apidra include hypoglycemia (low blood sugar), injection site reactions (redness, swelling, itching), and lipodystrophy (changes in fat distribution). Serious side effects can include severe hypoglycemia, allergic reactions, and hypokalemia (low potassium levels) [1].
How does Apidra compare to other rapid-acting insulins?
Apidra is comparable to other rapid-acting insulins such as Novolog (insulin aspart) and Humalog (insulin lispro) in terms of its onset, peak, and duration of action. These insulins are all designed to manage blood sugar spikes after meals [1].
What is the regulatory status of Apidra?
Apidra was approved by the U.S. Food and Drug Administration (FDA) in 2004 for the treatment of diabetes mellitus [1].
Sources
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021299lbl.pdf
2. https://www.drugpatentwatch.com/